JP4598273B2 - カルバペネム−３−カルボン酸の新規Ｃ−２Ｓ／Ｏ−及びＳ／Ｎホルムアルデヒドアセタール誘導体並びにそれらの抗生物質及びβ−ラクタマーゼインヒビターとしての使用 - Google Patents

カルバペネム−３−カルボン酸の新規Ｃ−２Ｓ／Ｏ−及びＳ／Ｎホルムアルデヒドアセタール誘導体並びにそれらの抗生物質及びβ−ラクタマーゼインヒビターとしての使用 Download PDF

Info

Publication number
JP4598273B2
JP4598273B2 JP2000562374A JP2000562374A JP4598273B2 JP 4598273 B2 JP4598273 B2 JP 4598273B2 JP 2000562374 A JP2000562374 A JP 2000562374A JP 2000562374 A JP2000562374 A JP 2000562374A JP 4598273 B2 JP4598273 B2 JP 4598273B2
Authority
JP
Japan
Prior art keywords
group
compound
mmol
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000562374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002521484A5 (enExample
JP2002521484A (ja
Inventor
ルドルフ プファエンドラー，ハンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002521484A publication Critical patent/JP2002521484A/ja
Publication of JP2002521484A5 publication Critical patent/JP2002521484A5/ja
Application granted granted Critical
Publication of JP4598273B2 publication Critical patent/JP4598273B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2000562374A 1998-07-28 1999-07-23 カルバペネム−３−カルボン酸の新規Ｃ−２Ｓ／Ｏ−及びＳ／Ｎホルムアルデヒドアセタール誘導体並びにそれらの抗生物質及びβ−ラクタマーゼインヒビターとしての使用 Expired - Fee Related JP4598273B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98114067.6 1998-07-28
EP98114067A EP0976752A1 (en) 1998-07-28 1998-07-28 C-2 S/O- and S/N-Formaldehyde acetal derivatives of carbapenem antibiotics
PCT/EP1999/005295 WO2000006574A1 (en) 1998-07-28 1999-07-23 NOVEL C-2 S/O- AND S/N FORMALDEHYDE ACETAL DERIVATIVES OF CARBAPENEM-3-CARBOXYLIC ACIDS AND THEIR USE AS ANTIBIOTICS AND β-LACTAMASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2002521484A JP2002521484A (ja) 2002-07-16
JP2002521484A5 JP2002521484A5 (enExample) 2006-09-14
JP4598273B2 true JP4598273B2 (ja) 2010-12-15

Family

ID=8232355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000562374A Expired - Fee Related JP4598273B2 (ja) 1998-07-28 1999-07-23 カルバペネム−３−カルボン酸の新規Ｃ−２Ｓ／Ｏ−及びＳ／Ｎホルムアルデヒドアセタール誘導体並びにそれらの抗生物質及びβ−ラクタマーゼインヒビターとしての使用

Country Status (17)

Country Link
US (1) US6482818B2 (enExample)
EP (2) EP0976752A1 (enExample)
JP (1) JP4598273B2 (enExample)
KR (1) KR20010086351A (enExample)
CN (1) CN1154649C (enExample)
AT (1) ATE243696T1 (enExample)
AU (1) AU760249B2 (enExample)
CA (1) CA2338776C (enExample)
DE (1) DE69909098T2 (enExample)
ES (1) ES2203164T3 (enExample)
HU (1) HUP0102729A3 (enExample)
IL (1) IL141114A (enExample)
MX (1) MXPA01000905A (enExample)
NZ (1) NZ509578A (enExample)
PT (1) PT1100800E (enExample)
WO (1) WO2000006574A1 (enExample)
ZA (1) ZA200100737B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE464280T1 (de) * 2004-08-23 2010-04-15 Sicor Inc Synthese von idarubin-aglycon
AU2008253257B2 (en) 2007-05-21 2013-10-03 Hans Rudolf Pfaendler Bactericidal anti-MRSA active pharmaceutical composition containing carbapenems
CN101412718B (zh) * 2007-10-19 2011-04-27 山东轩竹医药科技有限公司 含有硫基杂环胺甲酰基的碳青霉烯衍生物
CN103059028B (zh) * 2013-01-30 2014-05-07 山东罗欣药业股份有限公司 一种替比培南匹伏酯的制备方法
CN114957258A (zh) * 2021-02-25 2022-08-30 华东理工大学 基于碳青霉烯结构的广谱丝氨酸β-内酰胺酶抑制剂的合成及其在耐药细菌抑制中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116485A (ja) * 1981-12-29 1983-07-11 Shionogi & Co Ltd 新規抗生物質カルバペネム誘導体およびその製造法
JPS58124785A (ja) * 1982-01-20 1983-07-25 Shionogi & Co Ltd プルラシドマイシンｂおよびｃのデオキシ体ならびにその製造法
EP0079244B1 (en) * 1981-11-10 1986-12-30 Shionogi & Co., Ltd. Pluracidomycin b,c, and d and analogs thereof, their production and a microorganism for use therein
JPS6054387A (ja) * 1983-08-03 1985-03-28 メルク　エンド　カムパニ−　インコ−ポレ−テツド チエナマイシンの誘導体製造法
CA1285940C (en) * 1984-07-02 1991-07-09 Merck & Co., Inc. Carbapenems having a 2-quaternary heteroarylalkylthio substituent
IE851586L (en) * 1984-07-02 1986-01-02 Interchem Internat S A I methylcarbapenems having a 2-quaternary¹heteroarylalkylthio substituent
JPS63255283A (ja) * 1987-04-11 1988-10-21 Nippon Redarii Kk （１ｒ，５ｓ，６ｓ）−２−〔（３−置換イミダゾリニウム−１−イル）アルキル〕チオ−６−〔（ｒ）−１−ヒドロキシエチル〕−１−メチル−カルバペネム−３−カルボキシレ−ト
US5116833A (en) * 1990-10-19 1992-05-26 Bristol-Myers Squibb Company Antibiotic c-3 dithioacetal-substituted carbapenem compounds, compositions, and methods of use thereof

Also Published As

Publication number Publication date
DE69909098T2 (de) 2004-04-08
US6482818B2 (en) 2002-11-19
HUP0102729A2 (hu) 2002-01-28
MXPA01000905A (es) 2002-06-04
EP1100800B1 (en) 2003-06-25
EP1100800A1 (en) 2001-05-23
NZ509578A (en) 2003-06-30
CA2338776C (en) 2008-04-29
CN1154649C (zh) 2004-06-23
HUP0102729A3 (en) 2002-09-30
DE69909098D1 (de) 2003-07-31
IL141114A (en) 2004-02-08
CA2338776A1 (en) 2000-02-10
WO2000006574A1 (en) 2000-02-10
AU760249B2 (en) 2003-05-08
US20010031749A1 (en) 2001-10-18
JP2002521484A (ja) 2002-07-16
ES2203164T3 (es) 2004-04-01
IL141114A0 (en) 2002-02-10
AU5163999A (en) 2000-02-21
CN1311790A (zh) 2001-09-05
ATE243696T1 (de) 2003-07-15
EP0976752A1 (en) 2000-02-02
KR20010086351A (ko) 2001-09-10
ZA200100737B (en) 2002-07-25
PT1100800E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
HU182604B (en) Process for preparing penicilline esters
JP4598273B2 (ja) カルバペネム−３−カルボン酸の新規Ｃ−２Ｓ／Ｏ−及びＳ／Ｎホルムアルデヒドアセタール誘導体並びにそれらの抗生物質及びβ−ラクタマーゼインヒビターとしての使用
US4123539A (en) 6-Ethylpenicillanic acid
JPH0819135B2 (ja) 安定なオキサペネム‐３‐カルボン酸
AU609488B2 (en) (5r, 6s, 1r)-6-(1-hydroxyethyl)-2-(methoxymethyl)penem-3- carboxylic acid derivatives
JP2654201B2 (ja) 製薬学的調製物
BE848545A (fr) Derives n-methylene substitues de thienamycine,
KR910009270B1 (ko) 카바펜엠 항생제의 제조방법
JP2002521484A5 (enExample)
EP0548790B1 (de) (1'S)-Hydroxyalkyloxapenem-3-carbonsäuren und ihre Verwendung als Betalactamasehemmer
LU84739A1 (fr) Nouveaux antibiotiques de type carbapenem
CS259892B2 (en) Method of 6-(1-hydroxyethyl)-7-oxo-1-azabiclo/3,2,o/hept-en-2-carboxyl acid's derivatives production
CZ2001277A3 (cs) Nové C2 S/O- a S/N-formaldehydacetalové deriváty karbapenem-3-karboxylových kyselin a jejich použití jako antibiotik a inhibitorů Blaktamáz
US4172837A (en) Substituted 3-oxo-6-thia-2-azabicyclo (2.2.0) hexanes
HUP0500956A2 (en) Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them
JPH0429675B2 (enExample)
JPH06179676A (ja) カルバペネム、該カルバペネムを含有する抗菌作用を有する医薬調剤および該医薬調剤の製造法並びに該医薬調剤を製造するための中間体
US20040260084A1 (en) Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics
KR20030070011A (ko) 옥사페넴-3-카르복시산을 포함하는 제약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100924

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131001

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees